... price of palbociclib was reduced to 30%, 20% and 10% of the current price, the resultant incremental cost ... Kisqali, Novartis) has regulatory approval in multiple countries globally. It has primary patent protection until ...
This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and ...
... price competition among biologics and biosimilars . Monopolistic pricing practice in the generic market ... Kisqali Breast cancer , HER2 negative 8,476.31 Rucaparib Rubraca Ovarian cancer , BRCA 20,162.74 Abbreviations : ALK ...
Concentrating on a topic that has only been briefly touched upon by other texts, this book offers a focused perspective on the clinical presentation, underlying pathophysiologic mechanisms, and management of skin, hair, and nail conditions ...
This book explores topics of importance to all who have an interest in economic methods for assessment of the efficacy and effectiveness of new cancer treatments and in regulatory measures relating to their marketing authorization and ...
Finalist for the Pulitzer Prize in General Nonfiction A New York Times Bestseller Longlisted for the Andrew Carnegie Medal for Excellence in Nonfiction Winner of the WSU AOS Bonner Book Award Winner of the 2022 At Home With Growing Older ...
How to Get the Best Care at the Right Price Philip Moeller. APPENDIX 13 Asthma and Allergy Dupixent® - Dupixent ... Kisqali® - Novartis Universal Co - pay Card Lupron Depot® - Lupron Depot Savings Card Sprycel® - Sprycel Assist One ...
This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010.
Edited by Alexander Drilon and Michael Postow, the content of the book has been written by medical oncology fellows and each disease entity has been authoritatively reviewed by an oncologist with specific expertise in each subspecialty of ...
... price reduction based on income. They do not want patients to have to pay more than 20% of their annual income for the ... (Kisqali), ruxolitinib (Jakafi), sorafenib (Nexavar), sunitinib (Sutent), temsirolimus (Torisel), trametinib ...